Kunisaki Chikara, Makino Hirochika, Takagawa Ryo, Yamamoto Naoto, Nagano Yasuhiko, Fujii Syoichi, Kosaka Takashi, Ono Hidetaka A, Otsuka Yuichi, Akiyama Hirotoshi, Ichikawa Yasushi, Shimada Hiroshi
Department of Surgery, Gastroenterological Center, Yokohama City University, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan.
J Gastrointest Surg. 2008 May;12(5):802-10. doi: 10.1007/s11605-007-0385-7. Epub 2007 Oct 20.
This study aimed to identify predictive factors and to evaluate appropriate treatments for recurrence of esophageal cancer after curative esophagectomy. About 166 consecutive patients, who underwent curative esophagectomy, were enrolled between April 1994 and March 2003. Recurrence was classified as loco-regional or distant. Logistic regression analysis was used to identify predictive factors for recurrence. Prognostic factors were evaluated by Log-rank test and Cox proportional hazard regression analysis. The disease-specific 5-year survival was 56.8%. Recurrence was observed in 72 patients (43.4%), with 64 of these occurring within 3 years. The number of metastatic lymph nodes and lymphatic invasion independently predicted recurrence. There were significant differences in time to recurrence and survival time between loco-regional, distant recurrence, and combined recurrence. The 5-year survival time in patients with recurrence was 11.9%, and median survival time was 24 months. There was also a significant difference in survival after recurrence between treatment methods (no treatment vs chemo-radiotherapy, p=0.0063; chemotherapy, p=0.0247; and radiotherapy, p<0.0001). Meticulous, long-term follow-up is particularly necessary in patients with four or more metastatic lymph nodes to achieve early detection of recurrence. Randomized controlled trials should be used to develop effective modalities for each recurrence pattern to improve therapeutic outcomes.
本研究旨在确定预测因素,并评估食管癌根治性食管切除术后复发的合适治疗方法。1994年4月至2003年3月期间,连续纳入了约166例行根治性食管切除术的患者。复发分为局部区域复发或远处复发。采用逻辑回归分析确定复发的预测因素。通过对数秩检验和Cox比例风险回归分析评估预后因素。疾病特异性5年生存率为56.8%。72例患者(43.4%)出现复发,其中64例在3年内复发。转移淋巴结数量和淋巴管侵犯独立预测复发。局部区域复发、远处复发和联合复发在复发时间和生存时间方面存在显著差异。复发患者的5年生存时间为11.9%,中位生存时间为24个月。治疗方法之间复发后的生存也存在显著差异(未治疗与放化疗,p = 0.0063;化疗,p = 0.0247;放疗,p < 0.0001)。对于有四个或更多转移淋巴结的患者,尤其需要进行细致的长期随访,以实现复发的早期检测。应采用随机对照试验来开发针对每种复发模式的有效治疗方式,以改善治疗效果。